Triple

T1172151
Position Surface form Disambiguated ID Type / Status
Subject Tysabri E24936 entity
Predicate isTradeNameOf P24597 FINISHED
Object natalizumab E24936 NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: natalizumab | Statement: [Tysabri, isTradeNameOf, natalizumab]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: natalizumab
Context triple: [Tysabri, isTradeNameOf, natalizumab]
  • A. Tysabri chosen
    Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
  • B. Tecfidera
    Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
  • C. Remicade
    Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
  • D. Rituxan
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • E. Stelara
    Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07 
Target predicate: isTradeNameOf
Context triple: [Tysabri, isTradeNameOf, natalizumab]
  • A. tradeNameIncludes
    Indicates that a trade name contains another name or term as part of its full designation.
  • B. tradesAs
    Indicates that one entity conducts business or is publicly known under the trading name or brand of another entity.
  • C. hasTraditionalName
    Indicates that an entity is associated with a name traditionally used or recognized for it, often rooted in long-standing cultural or historical practice.
  • D. trademark
    Indicates that one entity legally owns and uses a distinctive sign, name, or symbol to identify and distinguish its goods or services from those of others.
  • E. isRelatedName
    Indicates that one name is connected to another through a variant, derivative, or otherwise non-identical but related naming relationship.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a494082a7c819095004f423f294a64 completed March 1, 2026, 7:31 p.m.
NER Named-entity recognition batch_69a4bceb3f188190b8b767380fe5986f completed March 1, 2026, 10:25 p.m.
NED1 Entity disambiguation (via context triple) batch_69ac6f1a13bc81909da2cfdbad397861 completed March 7, 2026, 6:31 p.m.
PD Predicate disambiguation batch_69a4bb5656948190b0b1d5446ad06005 completed March 1, 2026, 10:19 p.m.
PDg Predicate description generation batch_69a4bbd7ff1881908c943ecdfea59e81 completed March 1, 2026, 10:21 p.m.
Created at: March 1, 2026, 7:45 p.m.